MacroGenics, Inc. (NASDAQ:MGNX) Shares Bought by XML Financial LLC

XML Financial LLC grew its stake in MacroGenics, Inc. (NASDAQ:MGNX) by 31.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,169 shares of the biopharmaceutical company’s stock after purchasing an additional 5,569 shares during the period. XML Financial LLC’s holdings in MacroGenics were worth $75,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Armistice Capital LLC boosted its holdings in shares of MacroGenics by 150.0% in the second quarter. Armistice Capital LLC now owns 6,000,000 shares of the biopharmaceutical company’s stock valued at $25,500,000 after acquiring an additional 3,600,000 shares in the last quarter. Millennium Management LLC lifted its position in MacroGenics by 3,473.7% in the second quarter. Millennium Management LLC now owns 3,312,672 shares of the biopharmaceutical company’s stock valued at $14,079,000 after purchasing an additional 3,219,977 shares during the period. Marshall Wace LLP boosted its holdings in MacroGenics by 1,689.3% in the 2nd quarter. Marshall Wace LLP now owns 658,007 shares of the biopharmaceutical company’s stock valued at $2,797,000 after purchasing an additional 621,232 shares in the last quarter. Frazier Life Sciences Management L.P. increased its position in MacroGenics by 21.8% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,010,727 shares of the biopharmaceutical company’s stock worth $12,796,000 after purchasing an additional 539,023 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of MacroGenics by 39.3% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 661,914 shares of the biopharmaceutical company’s stock worth $2,178,000 after buying an additional 186,858 shares in the last quarter. Hedge funds and other institutional investors own 96.89% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price objective on shares of MacroGenics in a report on Wednesday, November 6th. StockNews.com raised shares of MacroGenics from a “sell” rating to a “buy” rating in a research note on Sunday, November 10th. Finally, JMP Securities cut shares of MacroGenics from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 7th. Eight research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $7.63.

MacroGenics Price Performance

Shares of NASDAQ MGNX opened at $3.16 on Friday. The firm’s 50-day moving average is $3.31 and its two-hundred day moving average is $3.67. MacroGenics, Inc. has a 12-month low of $2.91 and a 12-month high of $21.88. The company has a market capitalization of $198.33 million, a PE ratio of -2.00 and a beta of 2.04.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.